TEVA; TASE: TEVA), Sanofi-Aventis SA (NYSE: SNY; Euronext: SAN), and China's Sinopharm Group Co. Ltd. (HKSE: 1099; Pink Sheets: SHTDF) are three frontrunners to buy German generic-drug maker Ratiopharm GmbH as the deadline for second-round bids ends this week, according to "Bloomberg". The report is based on three sources close to the issue, who declined to be identified because the talks are private. Teva said in response that it does not respond to rumors.(Ver más...)
No hay comentarios:
Publicar un comentario